AZD6140

Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Oral antiplatelet therapy with P2Y12 receptor blockers (especially clopidogrel) is the current choice of treatment during acute coronary syndromes and percutaneous interventions. To address the various limitations of thienopyridine therapy (including response variability and non-responsiveness) a novel drug, AZD6140, is under clinical development. AZD6140 is an oral and reversible P2Y12 receptor blocker that does not require hepatic conversion to an active metabolite and produces an overall superior ADP-induced platelet inhibition with less response variability than clopidogrel. It has fast onset and offset actions that may be advantageous in patients who may have to undergo immediate surgery.

Original languageEnglish (US)
Pages (from-to)225-229
Number of pages5
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2007

Keywords

  • AZD6140
  • Coronary artery diseases
  • P2Y receptor blocker
  • Platelets
  • Thienopyridines

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'AZD6140'. Together they form a unique fingerprint.

  • Cite this

    Tantry, U. S., Bliden, K. P., & Gurbel, P. A. (2007). AZD6140. Expert Opinion on Investigational Drugs, 16(2), 225-229. https://doi.org/10.1517/13543784.16.2.225